MedTrace Logo

LAA Excision With AF Ablation Versus Oral Anticoagulants for Secondary Prevention of Stroke

NCT02478294 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 474

Last updated 2019-04-23

No results posted yet for this study

Summary

This cohort study aims to evaluate thoracoscopic left atrial appendage excision plus atrial fibrillation ablation versus oral anticoagulants for the prevention of stroke and non-central nervous systemic embolism in patients with atrial fibrillation and thromboembolism.

Conditions

Interventions

PROCEDURE

Thoracoscopic LAA Excision plus AF Ablation

In this group, patients receive thoracoscopic LAA excision plus AF ablation, which means thoracoscopic left atrial appendage excision plus atrial fibrillation ablation.

DRUG

Warfarin or Novel Oral Anticoagulants

In this group, patients receive warfarin or novel oral anticoagulants

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02478294 on ClinicalTrials.gov